

31 Jul 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's episode of Five Must-Know Things: large M&A deals under regulatory review; surprise at Roche's cardiovascular deal; BioNTech's multiple China partnerships; GSK preps for US RSV vaccine launch; and a look at the dynamic multiple myeloma market.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 28 July 2023, including: large M&A deals under regulatory review; surprise at [Roche Holding AG](#)'s cardiovascular deal; [BioNTech SE](#)'s multiple China partnerships; [GSK plc](#) preps for US RSV vaccine launch; and a look at the dynamic multiple myeloma market.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Reading The FTC Tea Leaves: Investors Await Insights For M&A](#)" - Scrip, 26 Jul, 2023.)

(Also see "[Eyebrows Raised As Roche Inks Cardiovascular Pact With Alnylam](#)" - Scrip, 24 Jul, 2023.)

(Also see "[Can BioNTech Take China Early-Stage Biotech Innovation Global?](#)" - Scrip, 26 Jul, 2023.)

(Also see "[GSK Confirms Arexvy Price And US Contract Negotiations Ahead Of Launch](#)" - Scrip, 26 Jul, 2023.)

(Also see "[Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves](#)"

- Scrip, 26 Jul, 2023.)

[Click here to explore this interactive content online](#) 